title: P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels.
abstract: The influence of cell culture conditions and previous drug exposure on P-glycoprotein (P-gp) expression levels in Caco-2 cells was determined. In this study, the expression of P-gp is demonstrated (i) visually by confocal laser scanning microscopy (CLSM), (ii) functionally by transport studies with substrates of the efflux pump, and (iii) quantitatively by flow cytometry (FCM) analysis using specific monoclonal antibodies (anti P-gp MRK 16 as an external antibody and P-GlycoCheck C219 as an internal antibody). Trypsinization of the cells after reaching confluence led to a decrease of P-gp expression levels, while trypsinization before reaching confluence led to an increase after long-term cultivation. Culturing the cells on polycarbonate filters did not elicit a significant change of P-gp expression over time in culture, whereas in plastic flasks (polystyrene) a decrease was detected. Using CLSM a strong fluorescence on the apical side of Caco-2 cell monolayers was observed, as a result of incubation with MRK 16 as primary and IgG Cy5 as secondary antibody. Previous drug exposure of the cells showed that verapamil, celiprolol, and vinblastine induced the P-gp expression, while metkephamid (MKA) decreased the P-gp expression level as compared to the control. Permeation studies consolidated the theory that P-gp is expressed in the Caco-2 cells examined. For talinolol and MKA, a higher transport from basolateral to apical side than from apical to basolateral could be measured. Incubation of the cell monolayer with MRK 16 reduced the secretion process to the apical side, but did not influence [3H]mannitol flux. Caco-2 cells seem to be a suitable cell line model for P-gp-mediated secretion studies. However, the variability of the P-gp expression requires careful control when this model is to be used in quantitative structure/secretion studies.
authors.affiliation: Department of Pharmacy, ETH, 8057 Zürich, Switzerland.
authors.forename: P
authors.initials: P
authors.lastname: Anderle
authors.forename: E
authors.initials: E
authors.lastname: Niederer
authors.forename: W
authors.initials: W
authors.lastname: Rubas
authors.forename: C
authors.initials: C
authors.lastname: Hilgendorf
authors.forename: H
authors.initials: H
authors.lastname: Spahn-Langguth
authors.forename: H
authors.initials: H
authors.lastname: Wunderli-Allenspach
authors.forename: H P
authors.initials: HP
authors.lastname: Merkle
authors.forename: P
authors.initials: P
authors.lastname: Langguth
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000032:analysis / Q000502:physiology*; D018938:Caco-2 Cells / Q000378:metabolism*; D004744:Enkephalin, Methionine / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D005434:Flow Cytometry; D006801:Humans; D018613:Microscopy, Confocal; D010539:Permeability; D011412:Propanolamines / Q000493:pharmacokinetics; D013997:Time Factors
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D011412:Propanolamines; C011550:talinolol; D004744:Enkephalin, Methionine; C028208:metkephamid